Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of GSK's RSV Maternal Vaccine in Healthy Women
NCT03674177Phase 1Completed
- Sponsor
- GSK
- Start
- Oct 2018
- Primary completion
- Apr 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus infection (RSV) (4 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Any and Grade 3 Solicited Local Adverse Events, Number of Subjects With Any, Grade 3 and Related Solicited General Adverse Events and 4 more. Started Oct 2018; status: completed.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03674177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03674177.